LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.

Hamasaki, Masato; Sakane, Naoki; Hara, Kazuo; Kotani, Kazuhiko

Hamasaki, Masato; Sakane, Naoki; Hara, Kazuo; Kotani, Kazuhiko.

Afiliação

Hamasaki M; Division of Community and Family Medicine, Jichi Medical University, Shimotsuke-City, Japan.
Sakane N; Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto-City, Japan.
Hara K; Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, Omiya-City, Japan.
Kotani K; Division of Community and Family Medicine, Jichi Medical University, Shimotsuke-City, Japan.

J Clin Lab Anal ; 35(11): e24056, 2021 Nov.

Article em En | MEDLINE | ID: mdl-34652028

Assuntos

LDL-Colesterol/sangue; Hiperlipoproteinemia Tipo II; Hipolipemiantes/uso terapêutico; Pró-Proteína Convertase 9/genética; Feminino; Humanos; Hiperlipoproteinemia Tipo II/sangue; Hiperlipoproteinemia Tipo II/tratamento farmacológico; Hiperlipoproteinemia Tipo II/epidemiologia; Hiperlipoproteinemia Tipo II/genética; Masculino; Pessoa de Meia-Idade; Mutação/genética

Palavras-chave

PCSK9 inhibitor; gain-of-function mutation; genetic hypercholesterolemia; lipid-lowering therapy; low-density lipoprotein receptor; statins

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Hiperlipoproteinemia Tipo II / LDL-Colesterol / Hipolipemiantes Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Lab Anal Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google